Serafin Morales Murillo
Grado: Doctor/a
973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat
ResearcherID: https://www.researcherid.com/rid/L-7216-2019
Publicaciones
-
Llombart-Cussac, A; Ramos, M; Dalmau, E; Garcia-Saenz, JA; Gonzalez-Farre, X; Murillo, L; Calvo, L; Morales, S; Carañana V; Gonzalez, A; Fernandez-Morales, LA; Moreno, F; Casas, MI; Angulo, MD; Camara, MC; Garcia-Mace, AI; Carrasco, E; Jara-Sanchez, C
Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study
EUROPEAN JOURNAL OF CANCER 58 122-129. .
-
Gavilá, J.; Lopez-Tarruella, S.; Saura, C.; Muñoz, M.; Oliveira, M.; De la Cruz-Merino, L.; Morales, S.; Alvarez, I.; Virizuela, J.A.; Martin, M.
SEOM clinical guidelines in metastatic breast cancer 2015
Clinical & Translational Oncology 17 946-955. .
-
Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer
BREAST CANCER RESEARCH AND TREATMENT 154 351-357. .
-
Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
CURRENT MEDICAL RESEARCH AND OPINION 31 1129-1137. .
-
Gil-Gil, M.J.; Bellet, M.; Morales, S.; Ojeda, B.; Manso, L.; Mesia, C.; Garcia-Martínez, E.; Martinez-Jáñez, N.; Melé, M.; Llombart, A.; Pernas, S.; Villagrasa, P.; Blasco, C.; Baselga, J.
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
BREAST CANCER RESEARCH AND TREATMENT 151 597-606. .
-
Martín M; Loibl S; von Minckwitz G; Morales S; Martinez N; Guerrero A; Anton A; Aktas B; Schoenegg W; Muñoz M; Garcia-Saenz JÁ; Gil M; Ramos M; Margeli M; Carrasco E; Liedtke C; Wachsmann G; Mehta K; De la Haba-Rodriguez JR
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
JOURNAL OF CLINICAL ONCOLOGY 33 1045-1045. .
-
Salazar, R.; Morales, S.; Gil-Martín, M.; Aguirre, E.; Oaknin, A.; Garcia, M.; Callies, S.; Wickremsinhe, E.R.; Benhadji, K.A.; Llombart, A.
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors
CANCER CHEMOTHERAPY AND PHARMACOLOGY 73 1205-1215. .
-
Aguirre, E.; Morales, S.; Llombart, A.
Other malignancies I. breast cancer
Other Malignancies I. Breast Cancer 235-251. .
-
Sanchez-Rovira, P.; Segui, M. A.; Llombart, A.; Aranda, E.; Anton, A.; Sanchez, A.; Lomas, M.; Jaen, A.; Fernandez, M.; Porras, I.; Dalmau, E.; Morales, S.; de la Haba-Rodriguez, J.
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
Clinical & Translational Oncology 15 810-817. .
-
Aguirre E; Taberner T; Luaña A; Morales S; Llombart A
Severe thrombocytopenia related to long-term trastuzumab exposure.
Tumori Journal 99 -. .
-
Martin, Miguel; Segui, Miguel A.; Anton, Antonio; Ruiz, Amparo; Ramos, Manuel; Adrover, Encarna; Aranda, Ignacio; Rodriguez-Lescure, Alvaro; Grosse, Regina; Calvo, Lourdes; Barnadas, Agusti; Isla, Dolores; Martinez del Prado, Purificacion; Ruiz Borrego, Manuel; Zaluski, Jerzy; Arcusa, Angels; Munoz, Montserrat; Lopez Vega, Jose M.; Mel, Jose R.; Munarriz, Blanca; Llorca, Cristina; Jara, Carlos; Alba, Emilio; Florian, Jesus; Li, Junfang; Lopez Garcia-Asenjo, Jose A.; Saez, Amparo; Jose Rios, Maria; Almenar, Sergio; Peiro, Gloria; Lluch, Ana; GEICAM 9805 Investigators
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
NEW ENGLAND JOURNAL OF MEDICINE 363 2200-2210. .
-
Aguirre Ortega, E.; Martín Marco, A.; Canal Sotelo, J.; Morales Murillo, S.; Llombart Cussac, A.
Dyspnea and persistent cough as first signs of distant recurrence disease
Medicina de Familia-SEMERGEN 36 597-599. .
Proyectos
- Diseño y testaje de péptidos de interferencia para el tratamiento del cáncer de mama triple negativo
- Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
- DEVELOPMENT OF PRECISION THERAPIES FOR TRIPLE NEGATIVE BREAST CANCERS BASED ON CRISPR/CAS9 RIBONUCLEOPROTEINS.
- Selección de tratamiento con quimioterapia neoadyuvante en pacientes con cáncer de mama en estadio precoz y con receptores hormonales positivos mediante la determinación de la plataforma ONCOTYPE, CF DNA en sangre periférica y cambios del marcador KI67 en tejido tumoral.
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
